INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 31 March 2016
|
Net Assets |
£186m |
|
Net Assets per share |
480p |
|
Share price |
411p |
|
Total value of unquoted investments |
£21m |
|
Total number of portfolio companies |
88 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Amgen |
8.1 |
|
Celgene |
8.0 |
|
Gilead |
8.0 |
|
Biogen |
6.7 |
|
Medivation |
5.8 |
|
Regeneron |
4.8 |
|
Alexion |
4.6 |
|
Ophthotech |
3.0 |
|
Incyte |
3.0 |
|
Genmab |
2.6 |
|
|
----------- |
|
Total |
54.6 |
|
Portfolio Revenue Split |
% NAV |
|
Revenue Generating |
79 |
|
Near Revenue |
2 |
|
No sales in the near term |
19 |
|
|
----------- |
|
Total |
100 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
84 |
|
Europe & UK |
16 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
89 |
|
Unquoted |
11 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
27 APRIL 2016